Skip to main content
Log in

Olanzapine, an atypical antipsychotic, increases rates of punished responding in pigeons

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

The effects of olanzapine [LY 170053; 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2, 3b][1,5]benzodiazepine), a potential atypical antipsychotic, were determined in pigeons whose keypeck responding was punished. These effects were compared to the anxiolytic agents chlordiazepoxide and pentobarbital, and to other antipsychotic agents. Keypeck behavior was maintained under a multiple FR30 FR30 schedule, signalled by white and red stimulus lights, respectively. Each component of the schedule alternated every 3 min with a 30-s timeout. During the white keylight component, responding was maintained by food presentation. During the red keylight component, responding was maintained by food and simultaneously suppressed by electric shock presentation, with response rates being only about 5% of those during the white stimulus light. Olanzapine (0.01–1.0 mg/kg) increased punished responding at doses below those which had an effect on unpunished responding. Clozapine (0.01–1.0 mg/kg), ritanserin (0.1–3.0 mg/kg), and, to a lesser extent, risperidone (0.1–1.0 mg/kg) were also effective at increasing punished responding. Generally, the maximum effect seen with olanzapine was equal to that seen with ritanserin, and it exceeded that seen with clozapine. However, these effects were generally less than those seen with chlordiazepoxide and pentobarbital. Haloperidol (0.01–0.1 mg/kg) was completely without effect on punished responding, while it caused decreases in unpunished behavior. These results provide further evidence that olanzapine has a profile in behavioral tests unlike the typical antipsychotic haloperidol. Moreover, this profile is similar to clozapine, a clinically effective antipsychotic with an atypical profile.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Azrin N (1959) A technique for delivering shock to pigeons. J Exp Anal Behav 2:161–163

    Google Scholar 

  • Barrett JE (1992) Recent developments in animal models of anxiety and anxiolytic drugs. In: Mendlewicz J, Racagni G (eds) Target receptors for anxiolytic and hypnotics: from molecular pharmacology to therapeutics. Karger, Basel

    Google Scholar 

  • Barrett JE, Witkin JM (1976) Interaction ofd-amphetamine with entobarbital and chlordiazepoxide: effects on punished responding behavior of pigeons. Pharmacol Biochem Behav 5:285–292

    Google Scholar 

  • Barrett JE, Witkin JM (1988) Buspirone in animal models of anxiety. In: Tunnicliff G, Eison AS, Taylor DP (eds) Buspirone: mechanisms and clinical aspects. Academic Press, New York

    Google Scholar 

  • Bleich A, Brown S, Kahn R, Van Praag HM (1988) The role of serotonin in schizophrenia. Schizophr Bull 14:297–315

    Google Scholar 

  • Brocco MJ, Koek W, Degryse AD, Colpaert FC (1990) Comparative studies on the anti-punishment effects of chlordiazepoxide, buspirone and ritanserin in the pigeon, Geller-Seifter and ogel conflict procedures. Behav Pharmacol 1:403–418

    Google Scholar 

  • Chopin P, Briley M (1987) Animal models of anxiety: the effect of compounds that modify 5-HT neurotransmission. Trends Pharmacol Sci 8:383–388

    Google Scholar 

  • Coward DM (1991) Pharmacological approaches to the development of atypical antipsychotics. In: Tamminga CA, Schulz SC (eds) Schizophrenia research. Raven Press, New York, pp 297–306

    Google Scholar 

  • Coward DM, Imperato A, Urwyler S, White TG (1989) Biochemical and behavioral properties of clozapine. Psychopharmacology 99:S6-S12

    Google Scholar 

  • Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481–483

    Google Scholar 

  • Cuelemans DLS, Hoppenbrouwers M, Gelders YG, Reyntjens AJM (1985) The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam. Pharmacopsychiatry 18:303–305

    Google Scholar 

  • Ekblom B, Haggstrom JE (1974) Clozapine (Leponex) compared with chlorpromazine: a double-blind evaluation of pharmacological and clinical properties. Curr Ther Res 16:945–957

    Google Scholar 

  • Ferster CB, Skinner BF (1957) Schedules of reinforcement. Appleton Century-Crofts, New York

    Google Scholar 

  • Fitton A, Heel RC (1990) Clozapine, a review of its pharmacological properties and therapeutic use in schizophrenia. Drugs 40:722–747

    Google Scholar 

  • Friedman RL, Sanders-Bush E, Barrett RJ (1985) Clozapine blocks disruptive and discriminative stimulus effects of quipazine. Eur J Pharmacol 106:191–193

    Google Scholar 

  • Fuller RW, Mason NR (1985) Flumezapine, an antagonist of central dopamine and serotonin receptors. Res Commun Chem Pathol Pharmacol 54:23–27

    Google Scholar 

  • Geller I, Seifter J (1960) The effects of meprobamate, barbiturates,d-amphetamine and promazine on experimentally induced conflict in the rat. Psychopharmacologia 1:482–492

    Google Scholar 

  • Gerlach J, Koppelhus E, Helweg E, Monrad A (1974) Clozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiatr Scand 50:410–424

    Google Scholar 

  • Gleeson S, Ahlers ST, Mansbach RS, Foust JM, Barrett JE (1989) Behavioral studies with anxiolytic drugs. VI. Effects on punished responding of drugs interacting with serotonin receptor subtypes. J Pharmacol Exp Ther 250:809–817

    Google Scholar 

  • Hippius H (1989) The history of clozapine. Psychopharmacology 99:S3-S5

    Google Scholar 

  • Janssen PAJ, Niemegeers CJE, Awouters F, Schellekens KHL, Megens AAHP, Meert TF (1988) Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 244:685–693

    Google Scholar 

  • Kane J, Honigfeld G, Singer J, Meltzer HY (1988) Clozapine for the treatment-resistent schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789–796

    Google Scholar 

  • Koek W, Jackson A, Colpaert FC (1992) Behavioral pharmacology of antagonists at 5-HT2/5-HT1Creceptors. Neurosci Biobehav Rev 16:95–105

    Google Scholar 

  • Krupp P, Barnes P (1992) Clozapine-associated agranulocytosis: risk and aetiology. Br J Psychiatry 160 [supp]:38–41

    Google Scholar 

  • Mansbach RS, Harrod C, Hoffman SM, Nader MA, Lei Z, Witkin JM, Barrett JE (1988) Behavioral studies with anxiolytic drugs. V. Behavioral and in vivo neurochemical analyses in pigeons of drugs that increase punished responding. J Pharmacol Exp Ther 246:114–120

    Google Scholar 

  • Meert TF, Janssen PAJ (1989) Psychopharmacology of ritanserin: comparison with chlordiazepoxide. Drug Dev Res 18:119–144

    Google Scholar 

  • Meltzer HY, Stahl SM (1976) The dopamine hypothesis of schizophrenia: a review. Schizophr Bull 2:19–76

    Google Scholar 

  • Meltzer HY, Matsubara S, Lee JC (1989) Classification of typical and atypical drugs on the basis of dopamine D-1, D-2 and serotonin2. J Pharmacol Exp Ther 251:238–246

    Google Scholar 

  • Moore NA, Tye NC, Axton MS, Risius FC (1992) The behavioral pharmacology of olanzapine, a novel “atypical” antipsychotic agent. J Pharmacol Exp Ther. 262:545–551

    Google Scholar 

  • Moore NA, Calligaro DO, Wong DT, Bymaster F, Tye NC (1993) The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Inv Drugs, 2:281–293

    Google Scholar 

  • Moore NA, Rees G, Sanger G, Tye NC (1994) Effects of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule. Behav Pharmacol 5:196–202

    Google Scholar 

  • Mosconi M, Chiamulera C, Recchia G (1993) New anxiolytics in development. Int J Clin Pharm Res XIII[6]:331–344

    Google Scholar 

  • Rasmussen K, Aghajanian GK (1988) Potency of antipsychotics in reversing the effects of a hallucinogenic drug on locus coeruleus neurons correlates with 5-HT2 binding affinity. Neuropychopharmacology 2:101–107

    Google Scholar 

  • Robertson A, MacDonald C (1984) Atypical neuroleptics clozapine and thioridizine enhance amphetamine-induced stereotypy. Pharmacol Biochem Behav 21:97–101

    Google Scholar 

  • Schmutz J, Eichenberger E (1982) Clozapine. Chronicles of Drug Discovery 1:39–59

    Google Scholar 

  • Shader RI, Mascio A (1970) Psychotropic drug side effects: chemical and theoretical perspectives. Williams and Wilkins, Baltimore

    Google Scholar 

  • Spealman RD, Katz JL (1980) Some effects of clozapine on punished responding by mice and squirrel monkeys. J Pharmacol Exp Ther 212:435–440

    Google Scholar 

  • Stille G, Lauener H, Eichenberger E. (1971) The pharmacology of 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzoiazepine (clozapine). II Farmaco 26:603–625

    Google Scholar 

  • Wiley JL, Compton AD, Porter JH (1993) Effects of four antipsychotics on punished responding in rats. Pharmacol Biochem Behav 45: 263–267

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Benvenga, M.J., Leander, J.D. Olanzapine, an atypical antipsychotic, increases rates of punished responding in pigeons. Psychopharmacology 119, 133–138 (1995). https://doi.org/10.1007/BF02246153

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02246153

Key words

Navigation